Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Assets: 2011-2025

Historic Assets for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $568.7 million.

  • Adma Biologics' Assets rose 45.59% to $568.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $568.7 million, marking a year-over-year increase of 45.59%. This contributed to the annual value of $488.7 million for FY2024, which is 48.45% up from last year.
  • As of Q3 2025, Adma Biologics' Assets stood at $568.7 million, which was up 1.85% from $558.4 million recorded in Q2 2025.
  • Adma Biologics' 5-year Assets high stood at $568.7 million for Q3 2025, and its period low was $232.8 million during Q2 2021.
  • Over the past 3 years, Adma Biologics' median Assets value was $376.4 million (recorded in 2024), while the average stood at $418.7 million.
  • In the last 5 years, Adma Biologics' Assets decreased by 5.53% in 2023 and then spiked by 48.45% in 2024.
  • Adma Biologics' Assets (Quarterly) stood at $276.3 million in 2021, then rose by 26.14% to $348.5 million in 2022, then decreased by 5.53% to $329.2 million in 2023, then skyrocketed by 48.45% to $488.7 million in 2024, then surged by 45.59% to $568.7 million in 2025.
  • Its Assets was $568.7 million in Q3 2025, compared to $558.4 million in Q2 2025 and $510.6 million in Q1 2025.